Abstract
Abstract We established orthotopic mouse models of human pancreatic cancer with fragments of BxPC-3-RFP tumor. Two weeks after implantation, mice were randomized to FGS or bright-field surgery (BS). FGS was performed 24 hrs after tail vein injection of anti-CEA-Alexa 488. Completeness of resection was assessed from pre- and postoperative images obtained with the OV-100 Small Animal Imaging System. Whole body images of mice were obtained postoperatively to assess for recurrence and mice were followed until premorbid to measure survival. We achieved a complete resection of pancreatic cancers in 92% of mice in the FGS group as compared to 58% in the BS group (p=0.002). Preoperative tumor burden was not significantly different between groups (p=0.424). However, FGS afforded a significantly smaller mean postoperative tumor burden compared to BS: 0.0004 ± SE 0.0003 mm2 vs. 0.0841 ± SE 0.027 mm2, p=0.004. On average, mice in the FGS experienced a greater reduction in tumor burden: 99.99% vs 97.72%, p=0.01. FGS reduced recurrence rates from 95% to 50% (p=0.002) and lengthened mean disease-free survival from 7 weeks to 30.5 weeks (p<0.001). The FGS group experienced longer overall survival compared to the BS group: 16.5 weeks vs. 37 weeks (p=0.001). Cure rate was improved with FGS from 5% to 50% (p=0.003). Furthermore, FGS more than doubled the one-year postoperative survival rate from 3 mice in the BLS group to 8 mice in the FGS group (p=0.005). This novel approach has potential to improve outcomes in the surgical treatment of pancreatic cancer. Survival and recurrence according to surgical mode. Surgical Mode Disease-Free Survival Overall Survival Recurrence Rate Bright-Field Surgery 7 weeks 16.5 weeks 95% Fluorescence-Guided Surgery 30.5 weeks 37 weeks 50% Citation Format: Cristina A. Metildi, Sharmeela Kaushal, Mark A. Talamini, George A. Luiken, Robert M. Hoffman, Michael Bouvet. Fluorophore-conjugated antibodies improve surgical resection of pancreatic cancer leading to prolonged disease-free survival and overall survival in orthotopic mouse models. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 726. doi:10.1158/1538-7445.AM2013-726
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.